Suncrete 3Q 2026: Revenue $140.96M, EPS ($0.01) — 10-Q Summary

Suncrete reported 3Q 2026 revenue of $140.96M, up 163.3% YoY, but net income fell 98.3% due to higher costs. Acquisitions contributed $85.1M in revenue. Gross margin declined to 28.1% from 37.0%. Adjusted EBITDA rose 63.6% to $22.4M. Future demand is expected to be supported by projects shifting into 2027, but elevated interest rates may constrain residential demand.

Original reporting
Published Nov 16, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Suncrete 3Q 2026: Revenue $140.96M, EPS ($0.01) — 10-Q Summary — source image
Decision brief

The 30-second read

$RMIXBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell‑offs, though the acquisition pipeline could support future upside.

02

Market read

The filing provides fresh earnings data that could influence Suncrete's stock and peers in the construction sector.

03

What to watch

Higher interest rates may dampen residential demand, but infrastructure projects could offset some weakness.

Relevance 7/10Novelty 8/10Timing: post‑market release

Background

Suncrete's 10‑Q shows rapid revenue growth from recent acquisitions but also significant cost inflation and a near‑total earnings loss.

Company-level read

Ticker impact

$RMIXBearishHigh confidence
Context

Suncrete reported Q3 2026 revenue of $140.96M and a loss of $0.01 per share in its 10‑Q filing.

Expected impact

likely downward pressure as the market prices in the loss and margin compression

Evidence & confidence

The company posted a 98.3% drop in net income and a sharp margin decline, which are bearish signals for investors.

Market effects

Construction and building‑materials sector may see broader scrutiny as margins tighten.

North American construction markets could feel pressure if similar cost dynamics spread.

Limited to firms with comparable acquisition‑driven growth models.

Counterpoint

Acquisition‑driven revenue surge could position Suncrete for longer‑term growth despite short‑term earnings pain.

Key entities

  • Suncrete, Inc.

    Construction materials firm reporting Q3 2026 results.

Related articles

$RMIXHigh

Suncrete: 3 Key Takeaways for Long-Term Investors

Suncrete (NASDAQ:RMIX) lowered its 2026 guidance due to slower residential building but expects steady demand from data center projects. Recent acquisitions are projected to add $200M-$250M in 2027 revenue. Management plans to offset input cost increases with annual price adjustments, aiming for EBITDA growth in 2027.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$RMIXMed

Suncrete Slips to Loss in Q3 2026, Misses Estimates

Suncrete, Inc. (RMIX) reported a Q3 2026 loss of $0.01 per share, missing estimates of $0.09. Revenue grew 163% to $141.0M, but net income was only $78,000. The stock fell 3.8% to $7.81. Management cited acquisitive growth and guided full-year revenue to $408.0M-$434.0M. Analysts remain bullish with 6 buy ratings.

$RMIXMed

Suncrete Q3 Earnings Call Highlights

Suncrete reported Q3 net income of $76,000, improving from a $37.1M loss in Q2. Adjusted EBITDA rose 66% to $22.4M. The company expects 2026 acquisitions to contribute $200M-$250M in 2027 revenue. Suncrete has $206.5M in total liquidity and plans a Q4 acquisition. Management expressed confidence in integrating recent acquisitions, with some taking up to 18 months.